cas 173838-67-0, 2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione

Articles about 173838-67-0Total 3 be found

Synthesis and Antibacterial Activity of Novel 4″-O-desosaminyl clarithromycin derivatives with 11, 12-arylalkyl side chains
A series of novel 4″-O-desosaminyl clarithromycin derivatives with 11, 12-arylalkyl side chains was synthesized by coupling 6-deoxy-desosamine donors (18, 19) with 4″-OH of compounds 5a–c. The activities of the target compounds were tested against a series of macrolide-sensitive and macrolide-resistant pathogens. Some of them showed activities against macrolide sensitive and resistant pathogens, and compounds 21d and 21e displayed significant improvement of activities against resistant pathogens.
Zhao, Zhe-Hui,Zhu, Di,Zhang, Xiao-Xi,Luo, Zhi-Gang,Lei, Ping-Sheng
p. 1 - 9
(2018/04/24)

Method of treating tuberculosis
Macrolide and ketolides, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the macrolides and ketolides, and compositions containing the same, also are disclosed.
-
Page/Page column 8

(2010/02/10)

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens
In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 μg/ml, bioavailability = 49%, AUC0-8 = 17.2 μg.h/l, t( 1/2 )= lh) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.
Denis, Alexis,Agouridas, Constantin,Auger, Jean-Michel,Benedetti, Yannick,Bonnefoy, Alain,Bretin, Francois,Chantot, Jean-Francois,Dussarat, Arlette,Fromentin, Claude,Gouin D'Ambrieres, Solange,Lachaud, Sylvette,Laurin, Patrick,Le Martret, Odile,Loyau, Veronique,Tessot, Nicole,Pejac, Jean-Marie,Perron, Sebastien
p. 3075 - 3080
(2007/10/03)